Streetbeat News

Products Services

VVOS

Vivos Therapeutics Inc (NASDAQ:VVOS) has announced two strategic agreements with Ormco and On Demand Orthodontist to provide Spark Clear Aligners to its national network of providers. This is expected to create additional revenue opportunities and expand Vivos' product line. The collaboration will also facilitate pricing discounts for Vivos' providers and joint marketing and sales support. The company expects faster treatment times and improved clinical outcomes for patients using Vivos CARE devices with Spark Aligners.

Portfolio Pulse from Vandana Singh

October 04, 2023 | 2:36 pm

BTCUSD

MARA

Marathon Digital Holdings Inc (NASDAQ:MARA) reported a 16% increase in Bitcoin production in September, driven by improved uptime and decreased curtailment activity at its Texas facility. The company's U.S. average operational hash rate increased 20% month-over-month. Marathon Digital also reported a higher percentage of total miner rewards available on the Bitcoin network. The company is considering expansion to international locations with low-cost renewable energy and plans to announce specifics in the coming weeks. Marathon sold 800 Bitcoin last month to support operations and held a total of 13,726 unrestricted Bitcoin as of September 30.

Portfolio Pulse from Adam Eckert

October 04, 2023 | 2:29 pm

META

Meta Platforms Inc (NASDAQ:META) has introduced new realistic metaverse avatars that could potentially be used to interact with deceased loved ones. However, CEO Mark Zuckerberg has expressed caution about the potential for such interactions to become unhealthy. The company's Reality Labs division, which lost $13.72 billion in 2022, is focusing on efficiency in 2023. Meta's shares have risen more than 150% year-to-date. The company's new Quest 3 AR/VR headset and avatar technology are garnering attention.

Portfolio Pulse from Adam Eckert

October 04, 2023 | 2:29 pm

GOOG

GOOGL

Google announced the pricing for its Pixel Watch 2 at $349 during the '23 Keynote Event.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 2:25 pm

FRLN

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) reported initial data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, a gene therapy candidate for Gaucher disease. The data showed favorable safety and tolerability, with no serious adverse events. Both patients treated showed several hundred-fold increases in GCase activity, a key enzyme deficient in Gaucher disease. Following the news, FRLN shares are up 5.05%.

Portfolio Pulse from Vandana Singh

October 04, 2023 | 2:23 pm

GOOG

GOOGL

Google has announced the Pixel Watch 2 during its #MadeByGoogle Keynote Event. The announcement was made live on YouTube.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 2:17 pm

KBR

KBR Inc has signed a Memorandum of Understanding (MoU) with SolydEra to offer an integrated solution for producing lower cost clean ammonia using renewable energy. KBR will integrate SolydEra's Solid Oxide Electrolysis (SOE) technology into its K-GreeN process to deliver highly efficient green ammonia capacity worldwide. The partnership is expected to deliver competitive levelized costs of carbon-neutral ammonia to accelerate the energy transition globally.

Portfolio Pulse from Shivani Kumaresan

October 04, 2023 | 2:04 pm

AMD

SSNLF

Samsung is rumored to be terminating its partnership with AMD for GPU development, as it plans to develop its own custom smartphone GPU. The underwhelming performance of the Xclipse 920 GPU, a part of the Exynos 2200, is cited as a possible reason for this decision. Samsung aims to increase competitiveness in various sectors, including automotive and AI, with an in-house GPU.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 1:52 pm

PLTR

Palantir Technologies Inc. (PLTR) is expanding its collaboration with PwC to combine its AI capabilities. The company has chosen the U.K. as its European headquarters for AI research and development. Palantir is also reportedly poised to secure a significant contract with the U.K.'s National Health Service (NHS), valued at approximately £480 million ($579 million). However, the financial impact of the NHS contract might not significantly influence Palantir's immediate financial results.

Portfolio Pulse from Nabaparna Bhattacharya

October 04, 2023 | 1:33 pm

MRNA

NVAX

Moderna, Inc (NASDAQ:MRNA) shares are trading higher after the company announced positive interim results from its Phase 1/2 trial of mRNA-1083, a combination vaccine against influenza and Covid-19. The vaccine has been selected to advance to Phase 3 trials, with regulatory approval targeted for 2025. Shares of competitor Novavax Inc (NASDAQ:NVAX) also surged after the FDA granted Emergency Use Authorization for its updated Covid-19 vaccine.

Portfolio Pulse from Adam Eckert

October 04, 2023 | 1:27 pm